🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Paul Sargos Piet Ost Vedang Murthy Derya Tilki, MD Pierre Blanchard, MD Piet dirix Tyler Seibert MD PhD Sean McBride Sean Collins Prostate SBRT @ USF Health Gert De Meerleer European Association of Urology (EAU) EAU Young Academics Dr. Tamim Niazi Brian C. Baumann Michael Hofman Alberto Briganti Ploussard Guillaume Alan Dal Pra, MD Overall the results make sense -- we know there is a PFS dose-response in intact disease, so it makes sense that when you refine to a post-op population with known macroscopic disease in the bed, dose-escalation would also improve PFS.

Paul Sargos Piet Ost Vedang Murthy Derya Tilki, MD Pierre Blanchard, MD Piet dirix Tyler Seibert MD PhD Sean McBride Sean Collins Prostate SBRT @ USF Health Gert De Meerleer European Association of Urology (EAU) EAU Young Academics Dr. Tamim Niazi Brian C. Baumann Michael Hofman Alberto Briganti Ploussard Guillaume Alan Dal Pra, MD SAKK 09/10 actually excluded these patients I believe, so your result is actually not inconsistent with SAKK 09/10 at all. In that trial, the failure of dose-escalation to even impact FFFP could be attributed to inherent uncertainties in localizing disease in the SRT setting.

Raffaella Lucchini Paul Sargos Thomas Zilli Vérane Achard Giulio Francolini David Pasquier Attractive idea, but I would recommend to wait some years with promotion - late scars might be common....

New ESTRO ACROP GUIDELINE on Prostate Bed Delineation for Postoperative Radiotherapy in Prostate Cancer! Great work!! ⁦Alan Dal Pra, MD⁩ ⁦Alfonso Gomez-Iturriaga⁩ ⁦Alberto Bossi⁩ sciencedirect.com/science/articl…

“These results support that TMT, in the setting of multidisciplinary shared decision making, should be offered to all suitable candidates with #MIBC and not only to patients with significant comorbidities for whom surgery is not an option.” thelancet.com/journals/lanon…

🧵1/ 🙏🏾🙏🏾🙏🏾Thank you patients, families, trial staff and investigators for participating in TROG Cancer Research 13.01 SAFRON II! This trial recruited n=90 across 13 sites in 🦘🇦🇺 and 🥝🇳🇿 between 2015-2018. We report the long-term 5-year outcomes at #ESTRO2023 live! #radonc #LCSM

Hey Nicolas Benziane-Ouaritini, first page in the latest edition of European Urology Oncology. 🤘🤘🤘🤘🤘🤘🤘🤘🤘🤘🤘 🕸️🕸️SPIDER STUDY🕸️🕸️ 🕷️Dose escalation in the salvage setting must be reevaluated, integrating modern imaging, in a prospective trial. Supiot Stéphane

👏👏👏

Thanks to Dr Carole Helissey Helissey carole for this great collaboration ! ➡️ Neoadjuvant CT + IO in 🫁 cancer. . pubmed.ncbi.nlm.nih.gov/38731244/ .

DARIUS trial protocol is online in European Urology Oncology ▶️Phase 2 randomized ▶️ Unfavorable intermediate risk prostate cancer ▶️ Radiotherapy + stADT Versus an ADT sparing approach using stDarolutamide ▶️58/62 patients included... ▶️PSA End as 1st objective sciencedirect.com/science/articl…

#Breastcancer #radiotherapy Witch dose metrics is the most representative to organs at risk? Results from serie of patients receiving 42 Gy to the breast🎗️, with or without nodal irradiation☢️, and 51 Gy integrated boost to tumor bed in 15 fractions. Great work @VVH Paul Sargos

Less is really more? Read our commentary in JAMA Oncology about NRG GU003 trial on hypofractionation in the post prostatectomy setting ☢️ Paul Sargos Thomas Zilli JAMA Oncology jamanetwork.com/journals/jamao…

Happy to announce that the PEACE 6 OligoPRESTO trial testing the role of metastasis directed therapy in hormone sensitive #ProstateCancer has completed accrual ahead of schedule. 550 patients randomized. Waiting now for data to mature.

🏴󠁧󠁢󠁥󠁮󠁧󠁿 In, European Urology Robert Huddart💙 has reported the results from the RAIDER prospective trial showing excellent oncological outcomes and safety, in a contemporary study of TMT for MIBC. 🇫🇷 Jonathan Khalifa 🎗️ Evanguelos Xylinas Our Editorial is here ⚡🌞: sciencedirect.com/science/articl…

⚡Prostate Cancer: which local radiotherapy (primary tumor ans metastases) for mHSPC ? Read our short Update in European Urology Focus Great collaboration with Paul Sargos and Alberto Bossi